171 related articles for article (PubMed ID: 6857425)
1. Hepatic complications of antituberculosis therapy revisited.
Cohen CD; Sayed AR; Kirsch RE
S Afr Med J; 1983 Jun; 63(25):960-3. PubMed ID: 6857425
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Schaberg T; Rebhan K; Lode H
Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Türktaş H; Unsal M; Tülek N; Orüç O
Tuber Lung Dis; 1994 Feb; 75(1):58-60. PubMed ID: 8161767
[TBL] [Abstract][Full Text] [Related]
4. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Girling DJ
Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
[TBL] [Abstract][Full Text] [Related]
5. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Tubercle; 1976 Jun; 57(2):81-95. PubMed ID: 134476
[TBL] [Abstract][Full Text] [Related]
7. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
8. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
[TBL] [Abstract][Full Text] [Related]
9. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
10. [Isoniazid-induced hepatic failure. Report of a case].
Pereira RM; Tresoldi AT; Hessel G
Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
[TBL] [Abstract][Full Text] [Related]
11. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
12. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
13. [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
Musch E; Loos U; Schwabe HK
Pneumologie; 1990 Feb; 44 Suppl 1():486-7. PubMed ID: 2367444
[TBL] [Abstract][Full Text] [Related]
14. Liver injury during antituberculosis treatment: an 11-year study.
Døssing M; Wilcke JT; Askgaard DS; Nybo B
Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
16. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
[TBL] [Abstract][Full Text] [Related]
17. [A case of acute hepatitis occurred during treatment with isoniazid and rifampicin (author's transl)].
Kameda K; Kawabata S; Shirai S
Kekkaku; 1980 May; 55(5):247-51. PubMed ID: 7412075
[No Abstract] [Full Text] [Related]
18. [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
Fiala W; Häcki MA; Brändli O
Schweiz Med Wochenschr; 1983 Dec; 113(51):1956-9. PubMed ID: 6658432
[TBL] [Abstract][Full Text] [Related]
19. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Nomi F; Hosaka K; Kurosawa T
Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
[TBL] [Abstract][Full Text] [Related]
20. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
